Scientific leaflet Eposin Teva [In Flemish], http://www.fagg.be/ (accessed July 2010).
2.
KimONKimWHLeeNY.Stability test of etoposide by concentration and time at IV admixture. J Korean Soc Hosp Pharm1997; 14(4): 310–313.
3.
BarthesDMRochardEBPouliquenIJRabouanSMCourtoisPY.Stability and compatibility of etoposide in 0.9% sodium chloride injection in three containers. Am J Hosp Pharm1994; 51(21): 2706–2709.
4.
BeijnenJHBeijnen-BandhoeAUDubbelmanACvan GijnRUnderbergWJ.Chemical and physical stability of etoposide and teniposide in commonly used infusion fluids. J Parenter Sci Technol1991; 45(2): 108–112.
JoelSPClarkPISlevinML.Stability of the i.v. and oral formulations of etoposide in solution. Cancer Chemother Pharmacol1995; 37(1–2): 117–124.
8.
LieSOAbrahamssonJClausenNForestierEHasleHHoviL. Nordic Society of Pediatric Hematology and Oncology (NOPHO); AML Study Group. Long-term results in children with AML: NOPHO-AML Study Group–report of three consecutive trials. Leukemia2005; 19(12): 2090–2100.
9.
Dutch-Belgian pediatric AML protocol for children with newly diagnosed acute myeloid leukaemia based on the NOPHO-AML 2004 study. (DB-AML-01), http://www.trialregister.nl/ (Accessed July 2010).
10.
GrodmanHWolfeLKretschmarC.Outcome of patients with recurrent medulloblastoma or central nervous system germinoma treated with low dose continuous intravenous etoposide along with dose-intensive chemotherapy followed by autologous hematopoietic stem cell rescue. Pediatr Blood Cancer2009; 53(1): 33–36.
11.
ZwickCBirkmannJPeterNBodensteinHFuchsRHänelM. Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone). Ann Hematol2008; 87(9): 717–726.
12.
Entz-WerleNSuciuSvan der Werff ten BoschJVilmerEBertrandYBenoitY. Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group report. Leukemia2005; 19(12): 2072–2081.
13.
ZhangYTrisselLA.Physical and chemical stability of etoposide phosphate solutions. J Am Pharm Assoc (Wash)1999; 39(2): 146–150.
14.
SparanoJAWiernikPHLeafADutcherJP.Infusional cyclophosphamide, doxorubicin, and etoposide in relapsed and resistant non-Hodgkin’s lymphoma: evidence for a schedule-dependent effect favoring infusional administration of chemotherapy. J Clin Oncol1993; 11(6): 1071–1079.
